ANTX AN2 Therapeutics, Inc.
Nasdaq · SEC CIK 1880438 · EDGAR
- Bought, last 12 months
- $11.6K 1 purchases by 1 insiders
- Sold, last 12 months
- $398.2K 13 sales by 6 insiders
- Filings on record
- 190 since 2022-03-31, latest 2026-09-16 17:35
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Readnour Robin Shane | Dir | — | $316.7K |
| Eizen Joshua M | See Remarks | — | $52.9K |
| FitzPatrick Margaret M | Dir | $11.6K | — |
| Chanda Sanjay | Chief Development Off | — | $9,311 |
| Day Lucy | CFO | — | $8,862 |
| Prior Stephen David | Chief Strategy Off | — | $7,363 |
| Williams Sarah Joanne | Principal Accounting Off | — | $3,025 |
| Trenor Cameron C. III | Chief Medical Off | — | — |
| Marks Gilbert Lynn | Dir | — | — |
| Martin Patricia A. | Dir | — | — |
Transactions 139
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2023-09-29 | 2023-09-27+ | ANTX | Aziz Kabeer | Dir, 10% | S - Sale | $16.11 | -9,357 | 2.18M | -0.4% | -$150.7K |
| 2023-09-15 | 2023-09-13 | ANTX | Adjuvant Global Health Technology Fund, L.P. | 10% | S - Sale | $16.00 | -336 | 2.18M | -0.0% | -$5,376 | |
| I | 2023-09-15 | 2023-09-13 | ANTX | Adjuvant Global Health Technology Fund, L.P. | 10% | S - Sale | $16.00 | -64 | 411.9K | -0.0% | -$1,024 |
| MI | 2023-09-15 | 2023-09-13 | ANTX | Aziz Kabeer | Dir, 10% | S - Sale | $16.00 | -400 | 2.18M | -0.0% | -$6,400 |
| M | 2023-09-08 | 2023-09-06+ | ANTX | Adjuvant Global Health Technology Fund DE, L.P. | 10% | S - Sale | $16.03 | -6,005 | 2.18M | -0.3% | -$96.3K |
| MI | 2023-09-08 | 2023-09-06+ | ANTX | Adjuvant Global Health Technology Fund DE, L.P. | 10% | S - Sale | $16.03 | -1,135 | 412.0K | -0.3% | -$18.2K |
| MI | 2023-09-08 | 2023-09-06+ | ANTX | Aziz Kabeer | Dir, 10% | S - Sale | $16.03 | -7,140 | 412.5K | -2% | -$114.5K |
| 2023-08-25 | 2023-08-23 | ANTX | Adjuvant Capital GP, L.P. | 10% | S - Sale | $16.00 | -336 | 2.18M | -0.0% | -$5,376 | |
| I | 2023-08-25 | 2023-08-23 | ANTX | Adjuvant Capital GP, L.P. | 10% | S - Sale | $16.00 | -64 | 413.1K | -0.0% | -$1,024 |
| MI | 2023-08-25 | 2023-08-23 | ANTX | Aziz Kabeer | Dir, 10% | S - Sale | $16.00 | -400 | 413.1K | -0.1% | -$6,400 |
| I | 2023-08-22 | 2023-08-18 | ANTX | RA Capital Nexus Fund II, L.P. | 10% | P - Purchase | $9.00 | +1.78M | 5.14M | +53% | +$16.00M |
| I | 2023-05-15 | 2023-05-15 | ANTX | Easom Eric | CEO, Dir | P - Purchase | $5.38 | +10.0K | 1.02M | +1.0% | +$53.8K |
| M | 2022-11-14 | 2022-11-10+ | ANTX | Easom Eric | CEO, Dir | S - Sale | $15.32 | -4,436 | 4,907 | -47% | -$68.0K |
| M | 2022-11-09 | 2022-11-08+ | ANTX | Easom Eric | CEO, Dir | S - Sale | $15.60 | -17.2K | 4,907 | -78% | -$267.8K |
| M | 2022-11-07 | 2022-11-03+ | ANTX | Easom Eric | CEO, Dir | S - Sale | $15.86 | -35.2K | 6,943 | -84% | -$558.2K |
| M | 2022-11-02 | 2022-10-31+ | ANTX | Easom Eric | CEO, Dir | S - Sale | $15.27 | -4,232 | 4,907 | -46% | -$64.6K |
| M | 2022-10-28 | 2022-10-27+ | ANTX | Easom Eric | CEO, Dir | S - Sale | $15.19 | -2,607 | 6,590 | -28% | -$39.6K |
| M | 2022-10-26 | 2022-10-24+ | ANTX | Easom Eric | CEO, Dir | S - Sale | $15.76 | -9,350 | 7,119 | -57% | -$147.4K |
| M | 2022-10-24 | 2022-10-20+ | ANTX | Easom Eric | CEO, Dir | S - Sale | $16.47 | -21.2K | 7,257 | -75% | -$349.9K |
| MI | 2022-08-05 | 2022-08-03+ | ANTX | Shah Rajeev M. | 10% | P - Purchase | $7.51 | +1,909 | 3.77M | +0.1% | +$14.3K |
| MI | 2022-07-28 | 2022-07-26+ | ANTX | RA Capital Nexus Fund II, L.P. | 10% | P - Purchase | $7.78 | +23.2K | 3.76M | +0.6% | +$180.7K |
| MI | 2022-06-24 | 2022-06-06 | ANTX | Aziz Kabeer | Dir, 10% | J - Other | $15.00 | 0 | 2.18M | New | $0 |
| DMA | 2022-06-24 | 2022-03-29 | ANTX | Adjuvant Global Health Technology Fund DE, L.P. | 10% | C - Cnv Deriv | — | +2.04M | 2.04M | New | — |
| DMAI | 2022-06-24 | 2022-03-29 | ANTX | Adjuvant Global Health Technology Fund DE, L.P. | 10% | C - Cnv Deriv | — | +386.6K | 386.6K | New | — |
| DA | 2022-06-24 | 2022-03-29 | ANTX | Adjuvant Global Health Technology Fund DE, L.P. | 10% | P - Purchase | $15.00 | +166.7K | 2.21M | +8% | +$2.50M |
| 2022-06-24 | 2022-06-06 | ANTX | Adjuvant Global Health Technology Fund, L.P. | 10% | J - Other | $15.00 | -26.5K | 2.18M | -1% | -$397.7K | |
| I | 2022-06-24 | 2022-06-06 | ANTX | Adjuvant Global Health Technology Fund, L.P. | 10% | J - Other | $15.00 | +26.5K | 413.2K | +7% | +$397.7K |
| I | 2022-06-23 | 2022-06-21 | ANTX | Shah Rajeev M. | 10% | P - Purchase | $7.99 | +302 | 3.75M | +0.0% | +$2,413 |
| MI | 2022-06-15 | 2022-06-13+ | ANTX | RA Capital Nexus Fund II, L.P. | 10% | P - Purchase | $7.95 | +81.4K | 3.69M | +2% | +$647.5K |
| D | 2022-03-31 | 2022-03-29 | ANTX | Zakrzewski Joseph S | Dir | C - Cnv Deriv | — | +98.2K | 98.2K | New | — |
| DMI | 2022-03-31 | 2022-03-29 | ANTX | Kolchinsky Peter | 10% | P - Purchase | $15.00 | +1.67M | 3.25M | +105% | +$25.00M |
| DMI | 2022-03-31 | 2022-03-29 | ANTX | Kolchinsky Peter | 10% | C - Cnv Deriv | — | +2.00M | 1.70M | New | — |
| DMI | 2022-03-31 | 2022-03-29 | ANTX | Readnour Robin Shane | Dir | C - Cnv Deriv | — | +751.6K | 405.0K | New | — |
| DMI | 2022-03-31 | 2022-03-29 | ANTX | Readnour Robin Shane | Dir | P - Purchase | $15.00 | +153.3K | 487.6K | +46% | +$2.30M |
| D | 2022-03-31 | 2022-03-29 | ANTX | Easom Eric | CEO, Dir | C - Cnv Deriv | — | +4,907 | 4,907 | New | — |
| DMI | 2022-03-31 | 2022-03-29 | ANTX | Adjuvant Global Health Technology Fund, L.P. | 10% | C - Cnv Deriv | — | +2.43M | 386.6K | New | — |
| DI | 2022-03-31 | 2022-03-29 | ANTX | Adjuvant Global Health Technology Fund, L.P. | 10% | P - Purchase | $15.00 | +166.7K | 2.21M | +8% | +$2.50M |
| DMI | 2022-03-31 | 2022-03-29 | ANTX | Aziz Kabeer | Dir, 10% | C - Cnv Deriv | — | +2.43M | 386.6K | New | — |
| DI | 2022-03-31 | 2022-03-29 | ANTX | Aziz Kabeer | Dir, 10% | P - Purchase | $15.00 | +166.7K | 2.21M | +8% | +$2.50M |
Purchase Sale Sale after option exercise All abbreviations